ESR1 and cancer: As described below, even within the context of breast cancers, ER+ cancers exhibit less abundant immune infiltrates, and generally develop fewer somatic mutations with concomitant reduced potential for tumor neo-antigens [36,37,38], compared to HER2+ and triple negative breast cancers (TNBC).